Vascepa (Icosapent Ethyl) Patent Expiration, LOE Window & CMS Spending

Vascepa (Icosapent Ethyl) by Amarin Ireland: FDA Orange Book LOE 2033-06-28, 12 AB generics, $771.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmarin Ireland
FDA Application & PathwayN202057 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-06-28
Orange Book Patents (*PED Extensions)61 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$771.6M
2024 Medicare Part D Spend$724.2M
2024 Medicaid Spend$47.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel